Adaptam’s approach focuses on disrupting the tumour microenvironment, which often prevents immune cells from effectively attacking cancer.
Adaptam Therapeutics has raised €3.0M across 1 funding round from 1 investor, most recently a Pre-Seed round in Oct 2025. Based in Barcelona, Spain; active in Healthtech. Data as of 7 Aug 2026.
Timing: in window vs cohort gap · momentum unknown. Funding-only estimates, not predictions and not investment advice — see signals.
| Date | Stage | Amount | Investors | |
|---|---|---|---|---|
| 2025-10-27 | Pre-Seed |
| €3.0M |
| Criteria Bio Ventures |
| View deal → |
